NID2 and metabolic dysfunction-associated steatotic liver disease: Additionally, reduced hepatic cholesterol efflux capacity in individuals with NAFLD has been linked to the presence of subclinical atherosclerosis [48], hinting that NID2 overexpression in hepatocytes may suppress cholesterol efflux, thereby leading to increased atherosclerosis.